Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients

Figures & data

Figure 1 Gating and staining strategy for the detection of MDMPs in FACS analysis (A-C).

Abbreviations: SSC, side scatter; FSC, forward scatter.

Table 1 Demographic and Clinical Characteristics of Cancer Patients and Healthy Controls

	Control	Cancer Patients	p value
n	40	138
Men/women (no.)	26/14	81/57
Age (years)	42 ± 11	53 ± 13	0.1946
BMI (kg/m^2)	25.1 ± 6.2	25.3 ± 9.2	0.6149
WBC (/µI)	58 ± 13	61 ± 24	0.5362
Hb (g/dL)	14.5 ± 2.9	12.7 ± 8.8	0.0175*
ROW-SD (fl)	43.3 ± 10.5	61.4 ± 22.6	0.0074*
Plt (×10^4/µI)	24.5 ± 3.9	27.3 ± 7.8	0.1375
MPV (fl)	9.12 ± 0.51	10.13 ± 1.13	0.0086*
FXllla (%)	89.2 ± 10.3	98.5 ± 13.2	0.0225*
sE-selectin (ng/mL)	43 ± 12	59 ± 26	0.0122*
sVCAM-1 (ng/ml)	613 ± 181	1556 ± 822	0.0094*
PAl-1 (ng/mL)	9.1 ± 2.7	36.2 ± 8.1	0.0012*
MCP-1 (pg/ml)	395 ± 91	482 ± 126	0.0338*
sCD14 (µg/mL)	2.3 ± 0.8	3.9 ± 1.2	0.0362*
MDMP (ev/µI)	39.4 ± 8.2	56.3 ± 10.2	0.0133*

Notes: Data are shown as mean ± SD. *Indicates statistical significance (P<0.05).

Abbreviations: BMI, body mass index; WBC, white blood cells; Hb, hemoglobin; RDW-SD, red blood cell distribution width-standard deviation; Plt, platelet count; MPV, mean platelet volume; FXIIIa, factor XIII activity; sE-selectin, soluble E-selectin; sVCAM-1, soluble VCAM-1; PAI-1, plasminogen activator inhibitor-1; MCP-1, monocyte chemotactic peptide; sCD14, soluble CD14; MDMPs, monocyte-derived microparticles.

Table 2 Multiregression Analysis of FXIIIa in Cancer Patients

	Univariate	p value	Multivariate
	β		β	p value
Age (years)	0.2362	0.08162
Sex (men)	− 0.0673	0.37952
BMI (kg/m^2)	0.2361	0.96373
WBC (/µI)	0.1759	0.28345
Hb (g/dL)	0.2392	0.09857
RDW-SD (fl)	0.3276	0.04811*	0.2336	0.11324
Plt (×0^4/µI)	0.3961	0.00923*	0.2751	0.07312
MPV (fl)	0.4355	0.00162*	0.3154	0.05982
sE-selectin (ng/mL)	0.3823	0.00713*	0.2861	0.06239
sVCAM-1 (ng mL)	0.4379	0.00192*	0.3365	0.04125*
PAI-1 (pg/mL)	0.4682	0.00188*	0.3589	0.01142*
MCP-1 (pg/mL)	0.5122	0.00136*	0.4327	0.03512*
sCD14 (µg/mL)	0.4962	0.00274*	0.3986	0.05013
MDMP (ev/µI)	0.6235	0.00018*	0.5943	0.00951*

Notes: β indicates standardized regression coefficients. *Indicates statistical significance (P<0.05).

Abbreviations: BMI, body mass index; WBC, white blood cells; Hb, hemoglobin; RDW-SD, red blood cell distribution width-standard deviation; Plt, platelet count; MPV, mean platelet volume; FXIIIa, factor XIII activity; sE-selectin, soluble E-selectin; sVCAM-1, soluble VCAM-1; PAI-1, plasminogen activator inhibitor-1; MCP-1, monocyte chemotactic peptide; sCD14, soluble CD14; MDMPs, monocyte-derived microparticles.

Table 3 Plasma Levels of Various Biomarkers in the Non-High FXIIIa and High FXIIIa Groups

	Non-High FXllla Group	High FXllla Group	p value
n	80	58
Men/women (no.)	50/30	31/27
Age (years)	51 ± 14	54 ± 12	0.6347
BMI (kg/m^2)	25.1 ± 7.4	25.5 ± 9.6	0.5988
WBC (/µI)	59 ± 19	63 ± 25	0.5873
Hb (g/dL)	13.1 ± 8.3	11.9 ± 9.5	0.2139
RDW-SD (fl)	56.4 ± 17.5	63.9 ± 24.2	0.0512
Plt (x10^4/µI)	23.9 ± 8.2	28.1 ± 10.2	0.0577
MPV (fl)	8.69 ± 0.93	10.92 ± 1.59	0.0538
sE-selectin (ng/mL)	51 ± 22	66 ± 29	0.0414*
sVCAM-1 (ng/ml)	1421 ± 733	1678 ± 925	0.0322*
PAI-1 (ng/mL)	25.1 ± 6.3	41.4 ± 8.1	0.0013*
MCP-1 (pg mL)	439 ± 112	482 ± 10.2	0.0105*
sCD14 (µg/mL)	3.7 ± 0.9	4.3 ± 1.6	0.0436*
MDMP (ev/µI)	50.2 ± 7.8	63.9 ± 15.1	0.0047*

Notes: Data are shown as mean ± SD. P-value, non-high FXIIIa group versus high FXIIIa group. *Indicates statistical significance (P<0.05).

Abbreviations: BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; RDW-SD, red blood cell distribution width-standard deviation; Plt, platelet count; MPV, mean platelet volume; FXIIIa, factor XIII activity; sE-selectin, soluble E-selectin; sVCAM-1, soluble VCAM-1; PAI-1, plasminogen activator inhibitor-1; MCP-1, monocyte chemotactic peptide; sCD14, soluble CD14; MDMPs, monocyte-derived microparticles.

Figure 2 Kaplan–Meier curves of overall survival of non-high FXIIIa and high FXIIIa patient groups.

Abbreviation: FXIIIa, factor XIII activity.